U.S. Markets closed

Cerulean Pharma Inc. (CERU)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.40-0.00 (-0.83%)
At close: 4:00PM EDT

0.40 -0.01 (-2.44%)
After hours: 5:33PM EDT

People also watch
Interactive chart
Previous Close0.41
Bid0.38 x 40000
Ask1.12 x 1000
Day's Range0.40 - 0.45
52 Week Range0.33 - 3.58
Avg. Volume3,372,974
Market Cap11.74M
PE Ratio (TTM)-0.29
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals2 months ago

    As Cerulean Pharma winds down, executives get a parting gift: bonuses

    After multiple trial failures, Waltham-based cancer drug developer Cerulean Pharma is laying off its employees, selling its lead drugs and merging with a San Diego biotech. Cerulean (CERU) announced on Monday that it will be absorbed by Daré Bioscience through a reverse merger, sell its two lead cancer drugs and its technology platform for a total of just $7.5 million, and lay off 11 of its 19 employees. The remaining eight employees, including CEO Christopher Guiffre, will remain with the company only through the close of the transaction.

  • American City Business Journals2 months ago

    Waltham's Cerulean Pharma to cut staff, merge with San Diego biotech

    Waltham-based cancer drug developer Cerulean Pharma said Monday that it plans to lay off more than half of its remaining employees, sell its lead drugs and combine forces with a San Diego biotech through a reverse merger. Cerulean (CERU) said it had reached a stock purchase agreement with Daré Bioscience under which the privately-held San Diego biotech’s shareholders will become the majority owners of Cerulean. The combined company will be listed on the Nasdaq and operate under Dare’s name.

  • TheStreet.com2 months ago

    Stick to Small, Fast Trades Until the Fed's out of the Way

    Betting on negative reaction to the Fed has not worked well in the past.